Senores Pharmaceuticals Key Ratios
NSE: SENORES | BSE: 544319
₹1,355.20
As on 25-Sep-2026IST
Market cap
₹6,245 Cr
Revenue (TTM)
₹692 Cr
P/E Ratio
49.4
P/B Ratio
6.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 2.87 | 35.95 | 53.57 | 161.60 | -- |
| EBIT | 14.74 | 92.70 | 117.98 | 132.61 | -- |
| Net Profit | -2.82 | 55.70 | 87.05 | 143.35 | -- |
| EPS | -2.82 | 55.70 | 74.33 | 42.86 | -- |
| Book Value | -- | -- | 18.71 | 63.52 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 18.23 | -- | 24.51 | 21.67 | 18.30 |
| Net Margin
| 15.63 | -- | 18.13 | 17.88 | 13.97 |
| Return on equity
| 17.37 | -- | 14.46 | 14.14 | 11.78 |
| Return on Capital
| 13.30 | -- | -- | 15.66 | 11.94 |
| Return on Assets
| 7.98 | -- | 9.24 | 8.64 | 6.43 |
| Debt to Equity (x)
| -- | -- | 0.21 | 0.35 | 0.39 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
--
|
15.66
|
11.94
|
12.31
|
18.56
|
|
Peer Median
|
--
|
14.03
|
16.46
|
15.49
|
--
|
ROE
14.46
Higher than Peers by 4.52
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
14.46
|
14.14
|
11.78
|
26.19
|
20.55
|
|
Peer Median
|
9.94
|
13.45
|
13.87
|
14.72
|
--
|
ROA
9.24
Higher than Peers by 1.70
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
9.24
|
8.64
|
6.43
|
8.86
|
8.89
|
|
Peer Median
|
7.54
|
7.94
|
8.04
|
7.19
|
--
|
EBIT Margin
24.51
Higher than Peers by 15.17
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
24.51
|
21.67
|
18.30
|
14.72
|
30.82
|
|
Peer Median
|
9.34
|
21.31
|
10.05
|
10.28
|
--
|
Net Margin
18.13
Higher than Peers by 8.78
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
18.13
|
17.88
|
13.97
|
15.05
|
21.61
|
|
Peer Median
|
9.35
|
11.88
|
9.11
|
6.78
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
--
|
24.15
|
18.88
|
19.91
|
28.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
53.57
Higher than Peers by 47.19
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
53.57
|
58.85
|
85.65
|
507.07
|
149.38
|
|
Peer Median
|
6.38
|
15.92
|
7.17
|
10.56
|
--
|
EBIT Growth
117.98
Higher than Peers by 119.02
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
117.98
|
88.13
|
130.79
|
189.87
|
773.38
|
|
Peer Median
|
-1.03
|
24.76
|
12.05
|
6.17
|
--
|
Net Profit Growth
87.05
Higher than Peers by 78.01
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
87.05
|
108.31
|
78.36
|
287.88
|
750.96
|
|
Peer Median
|
9.04
|
24.25
|
22.15
|
27.97
|
--
|
EPS Growth
74.33
Higher than Peers by 72.28
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
74.33
|
97.01
|
23.33
|
20.01
|
657.94
|
|
Peer Median
|
2.05
|
26.11
|
8.80
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
--
|
18.71
|
284.87
|
348.95
|
24.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.21
Higher than Peers by 0.19
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
0.21
|
0.35
|
0.39
|
1.22
|
1.34
|
|
Peer Median
|
0.02
|
0.17
|
0.03
|
0.05
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
--
|
0.03
|
0.04
|
0.16
|
0.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.92
Lower than Peers by 0.61
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
1.92
|
1.92
|
3.00
|
1.01
|
0.99
|
|
Peer Median
|
2.53
|
2.23
|
2.20
|
1.93
|
--
|
Quick Ratio
1.71
Lower than Peers by 0.07
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
1.71
|
1.71
|
2.77
|
0.86
|
0.93
|
|
Peer Median
|
1.78
|
1.82
|
1.72
|
1.59
|
--
|
Interest Coverage
7.34
Lower than Peers by 2.89
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
7.34
|
7.36
|
4.27
|
3.64
|
6.82
|
|
Peer Median
|
10.23
|
11.31
|
12.28
|
12.45
|
--
|
Operating Efficiency
Debtors to sales
46.96
Higher than Peers by 20.39
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
46.96
|
51.34
|
31.11
|
52.21
|
62.56
|
|
Peer Median
|
26.57
|
30.82
|
26.23
|
23.97
|
--
|
Asset Turnover
0.49
Lower than Peers by 0.18
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
0.49
|
0.45
|
0.44
|
0.58
|
0.37
|
|
Peer Median
|
0.67
|
0.72
|
0.74
|
0.88
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
--
|
129.44
|
108.09
|
114.09
|
215.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
--
|
42.09
|
43.08
|
34.45
|
31.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
--
|
218.97
|
182.04
|
217.67
|
296.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
--
|
-47.43
|
-30.87
|
-69.13
|
-49.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
49.42
Lower than Peers by 7.04
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
49.42
|
30.25
|
45.04
|
--
|
--
|
|
Peer Median
|
56.46
|
57.14
|
39.17
|
40.74
|
--
|
Price / Book Value
6.48
Higher than Peers by 1.66
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
6.48
|
3.74
|
3.35
|
--
|
--
|
|
Peer Median
|
4.82
|
4.95
|
3.61
|
3.87
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.13
|
0.11
|
0.19
|
0.20
|
--
|
EV/EBITDA
27.35
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
27.35
|
16.98
|
23.47
|
5.99
|
4.31
|
|
Peer Median
|
--
|
47.33
|
28.79
|
25.41
|
--
|
Market Cap
6,245
Lower than Peers by 132
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
6,245
|
3,490
|
2,638
|
--
|
--
|
|
Peer Median
|
6,377
|
6,311
|
3,944
|
2,959
|
--
|